Su1312 Carcinoembryonic Antigen (Cea) Level in Cyst Fluid of Pancreatic Cyst Has Poor Test Reliability and Should Not Be Used in Categorizing Incidental Pancreatic Cystic Lesions

2017 ◽  
Vol 85 (5) ◽  
pp. AB329-AB330
Author(s):  
Farhoud Khosravi ◽  
Mankanwal Sachdev ◽  
Ahmed Abdulameer ◽  
Ali Alshati ◽  
Sara Jackson ◽  
...  
Keyword(s):  
Carcinoembryonic Antigen ◽  
Pancreatic Cyst ◽  
Cyst Fluid ◽  
Test Reliability ◽  
Cystic Lesions

Co-analysis of pancreatic cyst fluid carcinoembryonic antigen and glucose with novel cut-off levels better distinguishes between mucinous and non-mucinous neoplastic pancreatic cystic lesions

2021 ◽  
pp. 000456322110539
Author(s):  
Burcu Barutcuoglu ◽  
Nevin Oruc ◽  
Güneş Ak ◽  
Serdar Kucukokudan ◽  
Ahmet Aydın ◽  
...  
Keyword(s):  
Carcinoembryonic Antigen ◽  
Pancreatic Cyst ◽  
Cyst Fluid ◽  
Added Value ◽  
Cystic Degeneration ◽  
Cystic Lesions ◽  
Characteristic Analysis ◽  
Glucose Levels ◽  
Pancreatic Cyst Fluid ◽  
Rule Out

Background Pancreatic cyst fluid analysis plays an important role in distinguishing between mucinous and non-mucinous cyst lesions. We aimed to compare the diagnostic performances of cyst fluid carcinoembryonic antigen (CEA), CA 19-9, and glucose in differentiating mucinous from non-mucinous neoplastic pancreatic cystic lesions (PCLs) and determine the best cut-off levels. Methods Patients’ data were evaluated retrospectively. 102 patients’ PCLs were grouped as non-neoplastic ( n = 25), non-mucinous neoplastic ( n = 20), mucinous neoplastic ( n = 47) and pancreatic adenocarcinomas with cystic degeneration ( n = 10); and CEA, CA 19-9, and glucose levels were compared. Receiver-operating characteristic analysis was performed, and the ideal cut-off values were determined. Results Cyst fluid CEA and CA 19-9, levels were significantly higher ( P < 0.001, P < 0.001, respectively) and glucose levels were significantly lower ( P = 0.001) in mucinous than in non-mucinous neoplastic PCLs. Area under curve with 95% confidence interval of CEA, glucose and CEA and glucose test combination was 0.939 (95% CI = 0.885–0.993, P = 0.001), 0.809 (95% CI = 0.695–0.924, P < 0.001) and 0.937 (95% CI = 0.879–0.995), respectively. CEA cut-offs to rule-in and rule-out mucinous neoplastic were 135.1 ng/mL (sensitivity = 62%, specificity = 94.7%) and 6.12 ng/mL (sensitivity = 94.1%, specificity = 80.4%), respectively. Glucose cut-off of 2.8 mmol/L was chosen both to rule-in and rule-out mucinous neoplastic PCLs (sensitivity = 78%, specificity = 80%). Co-analysis of CEA and glucose to distinguish mucinous from non-mucinous neoplastic PCLs had sensitivity = 87.8%, specificity = 93.3%, and diagnostic accuracy = 89.3%. Conclusions We concluded that co-analysis of cyst fluid CEA (cut-off = 135.1 ng/mL) and glucose (cut-off = 2.8 mmol/L) at novel cut-offs had the best testing performance to rule-in mucinous neoplastic PCLs. To rule-out mucinous PCLs co-analysis of CEA (cut-off = 6.12 ng/mL) and glucose (cut-off = 2.8 mmol/L) added value to prediction.

Quantitative real-time detection of carcinoembryonic antigen (CEA) from pancreatic cyst fluid using 3-D surface molecular imprinting

The Analyst ◽  
2016 ◽  
Vol 141 (14) ◽  
pp. 4424-4431 ◽  
Author(s):  
Yingjie Yu ◽  
Qi Zhang ◽  
Jonathan Buscaglia ◽  
Chung-Chueh Chang ◽  
Ying Liu ◽  
...  
Keyword(s):  
Carcinoembryonic Antigen ◽  
Real Time ◽  
Molecular Imprinting ◽  
Pancreatic Cyst ◽  
Cyst Fluid ◽  
Surface Molecular Imprinting ◽  
3D Surface ◽  
Real Time Detection ◽  
Pancreatic Cyst Fluid

In this study, a real time potentiometric biosensor based on the 3D surface molecular imprinting was developed for CEA detection.

scholarly journals Highly Accurate Identification of Cystic Precursor Lesions of Pancreatic Cancer Through Targeted Mass Spectrometry: A Phase IIc Diagnostic Study

2018 ◽  
Vol 36 (4) ◽  
pp. 367-375 ◽  
Author(s):  
Karolina S. Jabbar ◽  
Liisa Arike ◽  
Caroline S. Verbeke ◽  
Riadh Sadik ◽  
Gunnar C. Hansson
Keyword(s):  
Mass Spectrometry ◽  
Pancreatic Cancer ◽  
Carcinoembryonic Antigen ◽  
Validation Cohort ◽  
Malignant Potential ◽  
Cyst Fluid ◽  
High Grade Dysplasia ◽  
High Grade ◽  
Cystic Lesions ◽  
Accurate Identification

Purpose Pancreatic cystic lesions are common incidental findings on imaging, but up to half may be forerunners of pancreatic cancer. Therefore, accurate differential diagnosis is crucial for correct patient management. Unfortunately, currently available diagnostic methods cannot robustly identify premalignant and malignant pancreatic cystic lesions. Methods Cyst fluid samples obtained by routine endoscopic ultrasound-guided aspiration were used for the analyses. In a cohort of 24 patients, eight biomarker candidates for malignant potential and high-grade dysplasia/cancer were identified by an explorative proteomic approach. Subsequently, a quantitative analysis, using 30 heavy-labeled peptides from the biomarkers and parallel reaction monitoring mass spectrometry, was devised, tested in a training cohort of 80, and prospectively evaluated in a validation cohort of 68 patients. End points were surgical pathology diagnosis/clinical follow-up. Diagnostic assessments were blinded to mass spectrometry results. Results The optimal set of markers for detecting malignant potential was a panel of peptides from mucin-5AC and mucin-2, which could discriminate premalignant/malignant lesions from benign with an accuracy of 97% (95% CI, 89% to 99%) in the validation cohort. This result compared favorably with the accuracy of standard analyses: cyst fluid carcinoembryonic antigen (61%; 95% CI, 46% to 74%; P < .001) and cytology (84%; 95% CI, 71% to 92%; P = .02). A combination of proteins mucin-5AC and prostate stem-cell antigen could identify high-grade dysplasia/cancer with an accuracy of 96% (95% CI, 90% to 99%), and detected 95% of malignant/severely dysplastic lesions, compared with 35% and 50% for carcinoembryonic antigen and cytology ( P < .001 and P = .003, respectively). Conclusion Targeted mass spectrometry analysis of just three cyst fluid biomarkers provides highly accurate identification and assessment of cystic precursors to pancreatic adenocarcinoma. Additional studies should determine whether the method can facilitate timely cancer diagnosis, successful intervention, and prevention.

Value of adding GNAS testing to pancreatic cyst fluid KRAS and carcinoembryonic antigen analysis for the diagnosis of intraductal papillary mucinous neoplasms

2016 ◽  
Vol 29 (1) ◽  
pp. 111-117 ◽  
Author(s):  
Abdurrahman Kadayifci ◽  
Mustafa Atar ◽  
Jessica L. Wang ◽  
David G. Forcione ◽  
Brenna W. Casey ◽  
...  
Keyword(s):  
Carcinoembryonic Antigen ◽  
Pancreatic Cyst ◽  
Cyst Fluid ◽  
Intraductal Papillary Mucinous Neoplasms ◽  
Mucinous Neoplasms ◽  
Pancreatic Cyst Fluid
Sign in / Sign up

Export Citation Format

Share Document